--- title: "Weekly Recap | 10X Genomics +11.89%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/300192136.md" description: "10X Genomics (TXG) gained 11.89% this week to close at $85.71, outperforming the S&P 500’s 1.21% rise by around 10.68 percentage points. Trading was choppy before a late-week surge. The stock opened Monday at $79.15, slipped to an intraday low of $74.75 on Wednesday (Sep 23), then jumped 7.42% on Thursday (Sep 24) and pushed higher again on Friday (Sep 25), touching a range high of $86.16 before settling at $85.71. Average daily volume of about 3." datetime: "2026-09-26T07:11:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300192136.md) - [en](https://longbridge.com/en/news/300192136.md) - [zh-HK](https://longbridge.com/zh-HK/news/300192136.md) generator: "portal-rs" --- # Weekly Recap | 10X Genomics +11.89%, closing in on record highs ## The Week 10X Genomics (TXG) gained 11.89% this week to close at $85.71, outperforming the S&P 500’s 1.21% rise by around 10.68 percentage points. Trading was choppy before a late-week surge. The stock opened Monday at $79.15, slipped to an intraday low of $74.75 on Wednesday (Sep 23), then jumped 7.42% on Thursday (Sep 24) and pushed higher again on Friday (Sep 25), touching a range high of $86.16 before settling at $85.71. Average daily volume of about 3.46m shares ran more than 20% above the median, pointing to heavier turnover. ## Key Events Company-specific news on 10X Genomics was concentrated in the second half of the week. On Thursday, the stock rose 7.42%, with market reports pointing to strong demand for its new platform and a favourable patent development. Intraday on Friday, the shares climbed 10.26%, with reports attributing the move to strong new-platform demand and a patent victory that boosted confidence. Later that day, the company disclosed that CEO Serge Saxonov sold about $2.0m worth of common shares. Earlier in the week, ARK Invest’s activity in the biotech space drew attention, with Cathie Wood’s ETF positioning seen as part of a broader allocation shift toward the sector. No material company filings emerged from the week’s disclosure list. ## Analyst Ratings At the latest count, 18 firms cover 10X Genomics. Five rate it buy, one rates it overweight, and twelve rate it hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target price sits at $56.60, about 33.96% below the current price of $85.71. Target prices range from $40 to $90, reflecting wide dispersion. Within the life sciences tools and services industry, the stock ranks 10th out of 54 peers, in the upper-middle tier. ## The Week Ahead Next week brings a busy stretch of macro data. On Monday (Sep 28), the Dallas Fed manufacturing business activity index is due. On Tuesday (Sep 29), the calendar includes FHFA house prices, the Case Shiller 20-city home price index, JOLTS job openings and consumer confidence. For a growth name like 10X Genomics, macro liquidity and risk appetite may shape the external backdrop. Meanwhile, the market will keep watching whether demand for the new platform holds up, with product and sales clues from the third quarter still in focus. ## In Short This week’s rally in 10X Genomics arrived alongside news of strong new-platform demand and a patent win, with volume clearly elevated and the stock pressing against its recent highs. Yet the consensus target price remains well below spot, underscoring a gap between current valuation and analyst expectations. Within the sector, life sciences tools are drawing allocation interest tied to themes like AI infrastructure, while executive selling offers a counterweight signal. The key question ahead is whether new-platform revenue can follow through, and whether macro data and biotech sentiment align further. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TXG.US](https://longbridge.com/en/quote/TXG.US.md) ## Related News & Research - [10x Genomics (TXG) Could Be 50% Above Fair Value On Sentira And Atera Launches](https://longbridge.com/en/news/300832825.md) - [10x Genomics CEO Serge Saxonov disposes of USD 2,002,007.16 in common shares](https://longbridge.com/en/news/300073808.md) - [This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday](https://longbridge.com/en/news/300306438.md) - [Time to Nibble on MCD Stock After it Enters Oversold Territory?](https://longbridge.com/en/news/300812314.md) - [2 of the Best Warren Buffett Stocks for a Lifetime of Passive Income](https://longbridge.com/en/news/300803278.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**